Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company was founded in 2009 and is based in New York, New York.
IPO Year:
Exchange: NASDAQ
Website: nemauramedical.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/29/2022 | $12.00 | Buy | H.C. Wainwright |
| 12/2/2021 | $7.50 | Buy | EF Hutton |
SC 13G - Nemaura Medical Inc. (0001602078) (Subject)
4 - Nemaura Medical Inc. (0001602078) (Issuer)
H.C. Wainwright initiated coverage of Nemaura Medical with a rating of Buy and set a new price target of $12.00
EF Hutton initiated coverage of Nemaura Medical with a rating of Buy and set a new price target of $7.50
4 - Nemaura Medical Inc. (0001602078) (Issuer)
3 - Nemaura Medical Inc. (0001602078) (Issuer)
4 - Nemaura Medical Inc. (0001602078) (Issuer)
4 - Nemaura Medical Inc. (0001602078) (Issuer)
4 - Nemaura Medical Inc. (0001602078) (Issuer)
4 - Nemaura Medical Inc. (0001602078) (Issuer)
4 - Nemaura Medical Inc. (0001602078) (Issuer)
4 - Nemaura Medical Inc. (0001602078) (Issuer)
3 - Nemaura Medical Inc. (0001602078) (Issuer)
3 - Nemaura Medical Inc. (0001602078) (Issuer)
8-K - Nemaura Medical Inc. (0001602078) (Filer)
DEF 14C - Nemaura Medical Inc. (0001602078) (Filer)
NT 10-K - Nemaura Medical Inc. (0001602078) (Filer)
8-K - Nemaura Medical Inc. (0001602078) (Filer)
8-K - Nemaura Medical Inc. (0001602078) (Filer)
PRE 14C - Nemaura Medical Inc. (0001602078) (Filer)
8-K - Nemaura Medical Inc. (0001602078) (Filer)
25-NSE - Nemaura Medical Inc. (0001602078) (Subject)
8-K - Nemaura Medical Inc. (0001602078) (Filer)
10-Q - Nemaura Medical Inc. (0001602078) (Filer)
WEST PALM BEACH, Fla., April 11, 2024 /PRNewswire/ -- Anthony, Linder & Cacomanolis, PLLC is proud to announce that Partner Craig D. Linder has been selected to the 2024 Top 50 Lawyers in America list for securities law. This prestigious accolade is part of the 10th annual list honoring a select group of 50 lawyers who have demonstrated outstanding leadership and success within the securities law community in the Americas. America's Top 50 Lawyers identifies and highlights the accomplishments of the nation's most distinguished and skilled attorneys in all fields of practice of law. Only 50 lawyers in each state will receive this honor and be selected for this esteemed membership. This hon
Loughborough, UK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. ("Nemaura Medical" or the "Company"), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs, is providing a crucial update regarding recent decisions that will impact Nemaura Medical's listing status on The Nasdaq Capital Market and our broader strategic direction. Background: After thorough analysis, Nemaura Medical's Board of Directors and management team have made the strategic decision to accept Nasdaq's determination to delist Nemaura Medical and move to the OTC Markets. This decision arises from a careful consideration of several factors, including challenges outside of our cont
Loughborough, UK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ:NMRD) ("Nemaura Medical" or the "Company"), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce that the Nasdaq Hearings Panel granted the Company's request for continued listing pursuant to an exception, including certain interim milestones, that ultimately expires on April 1st, 2024, to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market. The Company plans to continue with its commercial endeavours while pursuing its plans to ensure timely compliance with the terms of the Nasdaq Hearing Panel's decision
Loughborough, UK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ:NMRD) ("Nemaura Medical" or the "Company"), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce the execution of a strategic agreement for a $10 million credit facility which is expected to support the Company's strategic growth plans. Recognizing the challenges associated with equity sales, particularly in the small-cap landscape on the Nasdaq, Nemaura Medical has proactively pursued a funding strategy that minimizes dilution and, the Company believes, aligns with the best interests of its valued shareholders. This $10 million credit facility, structu
Company CEO to discuss development at 1pm EST on 15th November 2023, at the Sidoti Virtual Investor Conference Loughborough, UK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, developer of a daily wear non-invasive glucose sensor, and digital healthcare programs today announced the UK launch of its ground-breaking approach to metabolic health and weight management by integrating continuous glucose monitoring (CGM) with its behavioral change program, Miboko, complemented by pharmaceutical interventions using GLP-1 agonists such as Ozempic, Wegovy and Mounjaro. This innovative offering, featuring education, lifestyle modifications, dietary guidance, exercise goals, and cutting-edge gl
Loughborough, England, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today released its financial results for the quarter ended September 30, 2023 and provided a business update. Corporate Highlights: 1.The Company continued to support its UK licensee with its endeavours to obtain reimbursement for the sensors in the UK. 2.Advanced development of the Company's BEATdiabetes offering in readiness for a commercial launch in due course. 3.Continued development
LOUGHBOROUGH, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the appointment of Nikolai Rozanov as strategic adviser in AI development. Mr Rozanov is a specialist in the field of artificial intelligence and was selected for inclusion by Forbes magazine in their '30 Under 30' list in the field of technology, a prestigious honour accorded to the best up-and-coming talent in the sector. The appointment of Mr Rozanov solidifies the Company's expertise in
Loughborough, England, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present business updates and developments at the Maxim Group Emerging Growth in A.I., virtual conference. The presentation will take place at 11am Eastern time on 27 September 2023. Register for the conference here: www.m-vest.com About Nemaura Medical, Inc. Nemaura Medical Inc. is a medical technology company developing and commercialising non-inv
LOUGHBOROUGH, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today provided an update regarding the status of its compliance with Nasdaq continued listed standards and anticipated next steps to maintain its listing on The Nasdaq Capital Market. As previously disclosed by the Company, the Nasdaq Listing Qualifications Staff (the "Staff") notified the Company by letters dated April 3, 2023, and April 7, 2023, that the Company no longer satisfied the minimum market value
LOUGHBOROUGH, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced interim results from its metabolic health program. The primary objective of the study was to establish whether a metabolic program with a daily wear CGM worn twice a month resulted in greater engagement levels and sustainable weight reduction, and how this compared to other programs. The multi-centered study was run in collaboration with the UK's National Health Service. Known as Miboko (Mi
ORLANDO, FL / ACCESSWIRE / November 4, 2022 / RedChip Companies will air a new interview with Nemaura Medical, Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, on The RedChip Money Report® on Bloomberg TV, this Saturday, November 5, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Interview highlights:In the exclusive RedChip Money Report interview, Nemaura's CEO Dr. Faz Chowdhury discusses Nemaura's continuous glucose sensor, the sugarBEAT®, its potential impact on the 500
Loughborough, England, June 30, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today provides a business update and releases its financial results for the fiscal year ended March 31, 2022. Corporate Highlights for FY2022: Commenced shipments of sugarBEAT® continuous glucose monitor (CGM) devices to its UK licensee, MySugarWatch Limited ("MSWL"), previously DB Ethitronix Limited. MSWL commenced mass educational and awareness campaigns to physicians in the UK via a
Loughborough, England, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today provides a business update and releases its financial results for the first fiscal quarter, ended June 30, 2021, of fiscal 2022. Recent Corporate Highlights: Launched a digital healthcare subscription service in the U.S. under the brand name BEAT®diabetes, targeted at over 25 million people with Type 2 diabetes and 88 million people with pre-diabetes in the U.S.Received positive feedback fro
Loughborough, England, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces financial results for its fiscal third quarter ending December 31, 2020 and provides a corporate update. Recent and Third Quarter Highlights include: The Company continues to build the management team and strengthen resources for commercial revenue generation. Launched http://www.beatdiabetes.life in the U.S. which offers a program designed to help prevent, manage, or reverse Type
LOUGHBOROUGH, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the appointment of Nikolai Rozanov as strategic adviser in AI development. Mr Rozanov is a specialist in the field of artificial intelligence and was selected for inclusion by Forbes magazine in their '30 Under 30' list in the field of technology, a prestigious honour accorded to the best up-and-coming talent in the sector. The appointment of Mr Rozanov solidifies the Company's expertise in
Loughborough, England, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:NMRD)("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces the appointment of Dr. Arash (Ash) Ghadar as Chief Operating Officer. "Ash will play an important role at Nemaura as we begin to scale up our manufacturing and distribution operations. He brings over 20 years of product development, management and leadership experience spanning both business and technical disciplines. His main area of expertise is in the medical devices sector, and primarily w
Loughborough, England, April 15, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the appointment of Samantha Sanders as its Global Head of Digital Programs. Samantha has over two decades of project development, management and customer service experience, delivering successful digital projects to market within the wellbeing, pharmaceutical and medical device sector, both locally and internationally. Prior to joining the Nemaura team, more recently Samantha has bee
Loughborough, England, March 04, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces the appointment of industry stalwart Alistair Longmuir as an advisor for their global product manufacture strategy. “Ally’s work in the medical device field make him a vital addition to the Nemaura team as we build our commercial manufacturing partnerships. His extensive experience in the methodologies of R&D, manufacturing and deep industry insight will help serve to guide us as we c
New York , Feb. 04, 2021 (GLOBE NEWSWIRE) -- Victory Square Technologies (CSE:VST) (OTCMKTS:VSQTF) completes acquisition of mobile health provider IV Hydreight in US$1.6 million deal click here Ceylon Graphite Corp (CVE:CYL) (OTCMKTS:CYLYF) (FRA:CCY) scales up drill program at H1 site in Sri Lanka click here Predictmedix Inc (CSE:PMED) (OTCQB:PMEDF) to deploy its Safe Entry Stations at this weekend's Super Bowl festivities in Tampa click here Loop Insights Inc (CVE:MTRX) (OTCQBRACMF) enters first pure e-commerce pilot with leading UK online electronics retailer click here Talon Metals Corp (TSE:TLO) (OTCMKTS:TLOFF) (FRA:TAO) hails latest PEA on giant US nickel project, which s
Loughborough, England, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces the appointment of Thomas Mortensen as head of E.U. commercial operations and marketing. “Tom is an important addition to our team, as he will head up our operations in the E.U for our planned direct to consumer product. His extensive experience throughout Europe will help us determine the best way to position our products for country-specific audiences, and we look forward to his lead
LOUGHBOROUGH, England, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces the appointment of Jay L. Warner, a 30-year veteran of the healthcare industry, as head of U.S. commercial operations. “Jay brings a wealth of experience to Nemaura, including his experience in developing and commercializing wearable devices applicable to the diabetes market. He has spent a significant portion of his career in that market, providing a solid understanding of the specifi
$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying The Dow Jones index closed lower by over 150 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Fortress Biotech The Trade: Fortress Biotech, Inc. (NASDAQ:FBIO) President, CEO and Chairman MD Lindsay Rosenwald acquired a total of 50,000 shares
Gainers Dermata Therapeutics (NASDAQ:DRMA) stock increased by 113.1% to $1.3 during Thursday's after-market session. The market value of their outstanding shares is at $4.6 million. Intelligent Bio Solutions (NASDAQ:INBS) shares increased by 19.17% to $0.36. The market value of their outstanding shares is at $3.1 million. Exagen (NASDAQ:XGN) shares increased by 15.33% to $2.18. The market value of their outstanding shares is at $37.1 million. Nemaura Medical (NASDAQ:NMRD) shares increased by 12.53% to $0.12. The market value of their outstanding shares is at $3.4 million. Inspire Veterinary (NASDAQ:IVP) shares increased by 9.85% to $0.38. The market value of their outstanding shares is
Shares of Mobileye Global Inc. (NASDAQ:MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance. For the fourth quarter, the company expects revenue of $634 million-$638 million (vs. $636.39 million) and adjusted operating income of $241 million-$247 million. The company's previous implied guidance was $623 million-$648 million in revenue. Wolfe Research analyst Shreyas Patil downgraded Mobileye Global from Outperform to Peer Perform. Mobileye Global shares dipped 23.5% to $30.37 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Minim, Inc. (NASDAQ:MINM) shares jumped 170.2% t
Gainers Portage Biotech (NASDAQ:PRTG) shares moved upwards by 20.6% to $1.7 during Wednesday's after-market session. The company's market cap stands at $33.6 million. BIMI Intl Medical (NASDAQ:BIMI) stock rose 9.62% to $2.05. The market value of their outstanding shares is at $23.7 million. Molecular Partners (NASDAQ:MOLN) shares increased by 9.6% to $5.48. The company's market cap stands at $180.0 million. Nemaura Medical (NASDAQ:NMRD) shares rose 9.28% to $0.14. The market value of their outstanding shares is at $4.0 million. Bright Green (NASDAQ:BGXX) stock rose 8.62% to $0.3. The company's market cap stands at $55.5 million. Celularity (NASDAQ:CELU) shares rose 6.04% to $0.3. The m
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Wednesday. The Dow traded down 0.52% to 37,518.35 while the NASDAQ fell 0.98% to 14,621.38. The S&P 500 also fell, dropping, 0.61% to 4,713.82. Check This Out: How To Earn $500 A Month From Apple Stock Following Tuesday's Slide Leading and Lagging Sectors Energy shares rose by 0.8% on Wednesday. In trading on Wednesday, real estate shares fell by 1.8%. Top Headline The number of job openings fell by 62,000 from the prior month to 8.790 million in November, compared to market estimates of 8.85 million. Equities Trading UP Sidus Space, Inc. (NASDAQ:SIDU) s
Shares of SoFi Technologies, Inc. (NASDAQ:SOFI) fell sharply during Wednesday’s session after Keefe, Bruyette & Woods downgraded rating on the stock. Keefe, Bruyette & Woods analyst Michael Perito downgraded SoFi from a Market Perform rating to an Underperform rating and lowered the price target from $7.50 to $6.50, citing recent outperformance and a change in the analyst's model. SoFi Technologies shares dipped 12.8% to $8.41 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers NexImmune, Inc. (NASDAQ:NEXI) shares rose 150.8% to $6.14 after gaining over 6% on Tuesday. Trinity Place Holdings Inc. (NYSE:TPHS) rose gained 62.6% to $0.1857. The company re
Gainers NexImmune (NASDAQ:NEXI) shares moved upwards by 230.5% to $7.85 during Wednesday's regular session. The market value of their outstanding shares is at $8.3 million. ABVC BioPharma (NASDAQ:ABVC) stock increased by 58.36% to $1.9. The market value of their outstanding shares is at $14.7 million. First Wave BioPharma (NASDAQ:FWBI) shares rose 33.76% to $5.11. The market value of their outstanding shares is at $3.4 million. Dyne Therapeutics (NASDAQ:DYN) stock moved upwards by 24.06% to $16.2. The company's market cap stands at $994.4 million. Voyager Therapeutics (NASDAQ:VYGR) shares moved upwards by 21.55% to $10.94. The company's market cap stands at $481.3 million. Elicio Thera
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 150 points on Wednesday. The Dow traded down 0.79% to 37,417.28 while the NASDAQ fell 1.01% to 14,616.58. The S&P 500 also fell, dropping, 0.78% to 4,705.94. Check This Out: How To Earn $500 A Month From Apple Stock Following Tuesday's Slide Leading and Lagging Sectors Energy shares rose by 0.6% on Wednesday. In trading on Wednesday, real estate shares fell by 2.2%. Top Headline The ISM Manufacturing PMI rose to 47.4 in December from 46.7 in the prior month, and topping than market estimates of 47.1. However, the recent reading signalled contraction in factory activity for the 14th
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 100 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.35% to 37,584.32 while the NASDAQ fell 0.66% to 14,668.39. The S&P 500 also fell, dropping, 0.49% to 4,719.52. Check This Out: How To Earn $500 A Month From Apple Stock Following Tuesday's Slide Leading and Lagging Sectors Health care shares rose by 0.1% on Wednesday. In trading on Wednesday, materials shares fell by 1.4%. Top Headline Shares of UniFirst Corporation (NYSE:UNF) fell around 7% on Wednesday after the company released earnings for its first quarter. UniFirst posted quarterly earnings of $2.
Gainers NexImmune (NASDAQ:NEXI) stock increased by 84.4% to $4.38 during Wednesday's pre-market session. The market value of their outstanding shares is at $4.6 million. ABVC BioPharma (NASDAQ:ABVC) shares moved upwards by 75.0% to $2.1. The company's market cap stands at $16.2 million. First Wave BioPharma (NASDAQ:FWBI) shares increased by 46.07% to $5.58. The market value of their outstanding shares is at $3.7 million. Dyne Therapeutics (NASDAQ:DYN) stock rose 45.4% to $18.99. The company's market cap stands at $1.1 billion. VolitionRX (AMEX:VNRX) shares increased by 19.04% to $1.25. The company's market cap stands at $98.3 million. Agios Pharmaceuticals (NASDAQ:AGIO) shares moved up